摘要
目的了解绍兴市1型艾滋病病毒(HIV-1)株的耐药变异情况。方法分析2013-2014年绍兴地区新确认未经抗病毒治疗的130例HIV-1感染者,以及2014年前抗病毒治疗满一年且病毒未抑制的34例感染者样本,采用反转录-聚合酶链式反应(RT-PCR)和巢式-聚合酶链式反应(Nested-PCR)方法扩增HIV-1的pol基因区全长,参照美国斯坦福大学HIV耐药数据库,确定HIV亚型及耐药突变位点。结果 34例新诊断HIV感染者及33例病毒未抑制感染者的样品检测到耐药突变,主要亚型为CRF01_AE和CRF07_BC。仅在病毒未抑制感染者中检测到针对核苷类反转录酶抑制剂(NRTIs)的耐药突变,主要类型有M184V(42.42%)、K70R(15.15%)、D67N(12.12%)。在新确认感染者和病毒未抑制感染者两组人群中,均检测到针对非核苷类反转录酶抑制剂(NNRTIs)耐药的突变,主要类型有V179D/E/T(10.00%和18.18%)、K103N(2.22%和21.21%);在病毒未抑制感染者中还有Y181CY(21.21%)、V90I(12.12%)、G190A(15.15%)。在反转录酶(RT)区和整合酶(IN)区仅检测到少量次要耐药突变。结论绍兴市HIV经抗病毒治疗后易产生耐药性,部分可在新感染人群中传播,应对HIV耐药变异加强监测。
Objective To investigate HIV drug resistance in Shaoxing. Methods Plasma samples were collected from 130 antiretroviraI naive patients between 2013 and 2014, and 35 antiretroviral patients. RT PCR and nest-PCR were used to amplify the pol gene fragments. The subtypes were analyzed, and confirmed to HIV drug resistance, and viral susceptibility according to the Surveillance Drug Resistance Mutations list recommended by WHO. Results The plasma samples of 34 antiretrovirai-naive patients and 35 antiretroviral patients finally presented drug resist ance mutations, with two kinds of subtypes including CRF01_AE and CRF07 BC. Only the antiretroviral-naive patients had the mutations to NRTIs, mainly including M184V（42.42%）, KTOR（15.15%）, D67N（12.12%）. Both groups had the mutations to NNRTIs, mainly including V179D/E/T （18. 18%）, K103N （21.21%）, Y181CY （21.21%）, V901（12. 12%） and G190A（15.15%）. There were minor resistance mutations in RT and IN. Conclusion It is easy to develop drug resistance after HAART, and the resistant strains may spread to new infections. We should strengthen the surveillance of drug resistance.
作者
曹栋卿
赵丹燕
何婷婷
傅利军
汤佳良
Cao Dongqing Zhao Danyan lie Tingting Fu Lijun Tang Jialiang(Shaoxing Center for Disease Control and Prevention, Shaoxing 312000, Zhejiang , China)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2017年第4期284-287,共4页
Chinese Journal of Aids & STD
基金
绍兴市科技局科技计划(2013B70065)~~
